Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide

por Rezaï, Keyvan, Lokiec, François, Grandjean, Isabelle, Weill, Sophie, de Cremoux, Patricia, Bordier, Vincent, Ekue, Richard, Garcia, Mickael, Poupon, Marie-France, Decaudin, Didier
Publicado 2007

Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy

por Vázquez, Ramiro, Riveiro, Maria E., Berenguer-Daizé, Caroline, O’Kane, Anthony, Gormley, Julie, Touzelet, Olivier, Rezai, Keyvan, Bekradda, Mohamed, Ouafik, L’Houcine
Publicado en Front Oncol (2021)

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non‐metastatic breast cancer

por Bernadou, Guillemette, Campone, Mario, Merlin, Jean‐Louis, Gouilleux‐Gruart, Valérie, Bachelot, Thomas, Lokiec, François, Rezai, Keyvan, Arnedos, Monica, Diéras, Véronique, Jimenez, Marta, Paintaud, Gilles, Ternant, David
Publicado en Br J Clin Pharmacol (2016)

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma

por Gaudio, Eugenio, Tarantelli, Chiara, Ponzoni, Maurilio, Odore, Elodie, Rezai, Keyvan, Bernasconi, Elena, Cascione, Luciano, Rinaldi, Andrea, Stathis, Anastasios, Riveiro, Eugenia, Cvitkovic, Esteban, Zucca, Emanuele, Bertoni, Francesco
Publicado en Oncotarget (2016)

Phase I Dose-Escalation Study of EZN-2208 (PEG-SN38), a Novel Conjugate of Poly(ethylene) Glycol and SN38, Administered Weekly in Patients With Advanced Cancer

por Patnaik, Amita, Papadopoulos, Kyriakos P., Tolcher, Anthony W., Beeram, Muralidhar, Urien, Saïk, Schaaf, Larry J., Tahiri, Sanaa, Bekaii-Saab, Tanios, Lokiec, François M., Rezaï, Keyvan, Buchbinder, Aby
Publicado 2013

Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer

por Alberini, Jean-Louis, Boisgard, Raphaël, Guillermet, Stéphanie, Siquier, Karine, Jego, Benoît, Thézé, Benoît, Urien, Saik, Rezaï, Keyvan, Menet, Emmanuelle, Maroy, Renaud, Dollé, Frédéric, Kühnast, Bertrand, Tavitian, Bertrand
Publicado en Mol Imaging Biol (2015)

Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.

por Valentina, Peta, Zhu, Jianhui, Lubman, David M., Huguet, Samuel, Bismut, Francoise Imbert, Bolbach, Gérard, Clodic, Gilles, Matheron, Lucrèce, Ngo, Yen, Raluca, Pais, Housset, Chantal, Rezai, Keyvan, Poynard, Thierry
Publicado en Clin Res Hepatol Gastroenterol (2020)

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

por Vázquez, Ramiro, Riveiro, María E, Astorgues-Xerri, Lucile, Odore, Elodie, Rezai, Keyvan, Erba, Eugenio, Panini, Nicolò, Rinaldi, Andrea, Kwee, Ivo, Beltrame, Luca, Bekradda, Mohamed, Cvitkovic, Esteban, Bertoni, Francesco, Frapolli, Roberta, D'Incalci, Maurizio
Publicado en Oncotarget (2016)

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations

por Riveiro, Maria E., Astorgues-Xerri, Lucile, Vazquez, Ramiro, Frapolli, Roberta, Kwee, Ivo, Rinaldi, Andrea, Odore, Elodie, Rezai, Keyvan, Bekradda, Mohamed, Inghirami, Giorgio, D'Incalci, Maurizio, Noel, Kay, Cvitkovic, Esteban, Raymond, Eric, Bertoni, Francesco
Publicado en Oncotarget (2016)

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance

por Tarantelli, Chiara, Bernasconi, Elena, Gaudio, Eugenio, Cascione, Luciano, Restelli, Valentina, Arribas, Alberto Jesus, Spriano, Filippo, Rinaldi, Andrea, Mensah, Afua Adjeiwaa, Kwee, Ivo, Ponzoni, Maurilio, Zucca, Emanuele, Carrassa, Laura, Riveiro, Maria E, Rezai, Keyvan, Stathis, Anastasios, Cvitkovic, Esteban, Bertoni, Francesco
Publicado en ESMO Open (2018)

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

por Cottu, Paul H., Bonneterre, Jacques, Varga, Andrea, Campone, Mario, Leary, Alexandra, Floquet, Anne, Berton-Rigaud, Dominique, Sablin, Marie-Paule, Lesoin, Anne, Rezai, Keyvan, Lokiec, François M., Lhomme, Catherine, Bosq, Jacques, Bexon, Alice S., Gilles, Erard M., Proniuk, Stefan, Dieras, Veronique, Jackson, David M., Zukiwski, Alexander, Italiano, Antoine
Publicado en PLoS One (2018)